| Today’s Big NewsNov 16, 2023 |
| By Gabrielle Masson Merck & Co. is running out of time to get the first chronic cough medicine to market. So far, its path has been wrought with delays and the future appears no different as the FDA expresses new doubt about the pharma’s candidate gefapixant. |
|
|
|
By Annalee Armstrong Almost a year to the day after Roche revealed that its Alzheimer's drug gantenerumab failed a phase 3 trial, the data are appearing in The New England Journal of Medicine, giving scientists a chance to reflect on what was learned. |
By Nick Paul Taylor Astellas has shared a detailed look at the four deaths in its AT132 gene therapy clinical trial. Writing in The Lancet Neurology, the drugmaker explained that the liver toxicity seen in the trial differs from cases linked to other therapies—and made the case that the drug can provide transformative clinical benefits. |
Sponsored by Questex Fierce Biotech sits down with digital marketing leaders to discuss this year's most innovative topics at Fierce Biotech Summit and New Product Planning |
|
Reduce sequence artifacts that dampen variant calling sensitivity. Prepare highly complex libraries in under 1.5 hours, and minimize damage and loss with precious low-input and FFPE material. Learn more. 
|
|
By Nick Paul Taylor Astellas is spinning up a new attack on a cancer market, paying $175 million to buy Propella Therapeutics and its clinical-phase challenger to Johnson & Johnson’s fast-fading prostate cancer blockbuster Zytiga. |
By Annalee Armstrong Patients with neurofibromatosis type 1 have an option for treatment: AstraZeneca’s Koselugo. But it’s “a difficult drug to take,” according to SpringWorks Therapeutics CMO Jim Cassidy, M.D. That’s where his biotech is hoping to make its move, and a batch of mid-stage data seems to support the case. |
By Max Bayer Changes have been afoot at 858 Therapeutics, an RNA biotech tackling cancer and CNS disorders. The company recently laid off an unspecified number of staffers in the research group to preserve funds and funnel money toward clinical development work in 2024. |
By James Waldron While the IPO markets are unlikely to unfreeze next year, according to Sofinnova's Antoine Papiernik, the "silver lining" is Big Pharma's appetite for M&A. |
By Helen Floersh New preclinical research on Daiichi Sankyo’s antibody-drug conjugate DS-7300a suggests it might be more effective against hard-to-treat forms of prostate cancer when used alongside a long-standing chemotherapy drug. |
By Andrea Park In its second and third such notices this week, the FDA doled out its most serious label to recalls of syringe devices used in medication delivery. |
By Angus Liu Watch out, Pfizer and Roche. Thanks to an acquisition and now an FDA approval, Bristol Myers Squibb is entering a niche lung cancer market. |
By Noah Tong PBMs were a source of bipartisan agreement during a House hearing on Tuesday, while Republicans and Democrats clashed over durable medical equipment legislation. |
Fierce podcasts Don’t miss an episode |
| In this week’s episode of "Podnosis," you'll hear from two journalists from the Fierce Healthcare team: Paige Minemyer, senior editor of Fierce Health Payer, and Dave Muoio, a staff writer for Fierce Healthcare. Together, they guide you through their key insights from the inaugural Fierce Health Payer Summit in Austin and dive into the latest earnings updates from the largest health plans and health systems. |
|
|---|
|
|
Webinar Watch now to explore the convergence of science, capital, operational excellence and workplace strategy. Sponsored by: JLL |
Whitepaper A critical area to consider in selecting a CDMO is their ability to successfully complete technology transfers, which involves an intricate set of activities and disciplines that, if done incorrectly, could result in delays and failures that impact the overall success of your end product. Recognizing what it takes to complete this process effectively and efficiently is crucial to selecting the best partner for your project and product needs. This white paper delivers an analysis of critical success factors for effective technology transfer. Sponsored by: Lonza |
Whitepaper Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
Whitepaper Download our whitepaper to learn about plasmid DNA design considerations for cell and gene therapy applications. Sponsored by: Aldevron, a GMP manufacturing CDMO of DNA, RNA, and Proteins |
Whitepaper This paper explores AI’s potential impact on healthcare and on Medical Affairs (MA) more specifically. It also outlines what MA teams can do now to proactively leverage AI to improve service to their stakeholders. Presented by Blue Matter, strategic consultants in the life sciences |
eBook Emulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
Whitepaper Accelerate drug discovery with high-performance computing (HPC) powered by the cloud Sponsored By: AWS, NVIDIA, and Rescale |
| Edison Ballroom, New York City |
|
|
| |
|
